Allarity Therapeutics (NASDAQ:ALLR) Announces Quarterly Earnings Results

Allarity Therapeutics (NASDAQ:ALLR) posted its earnings results on Friday. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.18), FiscalAI reports. The business had revenue of $0.01 million for the quarter. Allarity Therapeutics updated its FY 2026 guidance to -0.760–0.730 EPS and its Q4 2026 guidance to 0.010-0.040 EPS.

Allarity Therapeutics Trading Up 4.4%

ALLR traded up $0.04 during trading on Friday, hitting $0.95. The stock had a trading volume of 279,178 shares, compared to its average volume of 151,355. The firm has a market cap of $15.17 million, a PE ratio of -1.22 and a beta of 0.57. Allarity Therapeutics has a 12 month low of $0.77 and a 12 month high of $1.84. The company has a 50 day simple moving average of $1.02 and a 200-day simple moving average of $1.21.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Thursday, October 15th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.25.

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates. Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology.